advertisement
Abstract #19105 Published in IGR 3-1
Reduction of ocular pulse amplitude as effect of Apraclondin: prospective double masked, randomized clinical trial in 10 subjects
Kuba GB; Austermann PKlinische Monatsblätter für Augenheilkunde 2001; 218: 187-191
BACKGROUND: The α-agonist Apraclondin lowers effective the intraocular pressure (IOP). Ischemia gains increasing importance in the pathogenesis of glaucoma. Therefore, an antiglaucomatous drug should also be investigated with regard to its influence on ocular hemodynamics. METHODS: In a double masked, randomized, clinical trial, 0.5% Apraclondin eye drops were applied in ten healthy subjects twice daily for eight days. The control group (ten healthy volunteers) received a placebo medication (0.9% NaCl) according to the same protocol. IOP, heart rate, blood pressure, and ocular pulse amplitudes (OBF Labs, UK) were measured at baseline (1T0), 90 minutes after instillation of one eye drop (1T90), after seven days of therapy (8T0), and again 90 minutes after an acute instillation (8T90). The Wilcoxon test for paired samples was used for statistical analysis. RESULTS: In Apraclonidin-treated subjects, IOP dropped significantly (p < 0.01) from 15.6 to 11.4/12.4/10.3 mmHg (1T0/1T90/8T0/8T90). The control group showed a significant drop at 8T0 (p = 0.02). Blood pressure remained constant in both groups, heart rate showed a drop in the control group at 1T90. In Apraclonidin-treated subjects, the pulse amplitude showed a significant reduction at 1T90 (p = 0.01) and at 8T90 (p = 0.005), from 3.22 to 2.48/3.1/2.35 mmHg (1T0/1T90/8T0/8T90), while the pulse amplitude remained constant in the control group. CONCLUSIONS: After one week of therapy with 0.5% Apraclonidin, IOP dropped in healthy volunteers as expected. However, the reduction observed in pulse amplitudes could have a negative effect on long-term therapy in patients with chronic open-angle glaucoma. LA: German
Dr G.B. Kuba, Medizinisches Zentrum für Augenheilkunde der Philipps-Universität Marburg, Robert-Koch-Strasse 4, 35037 Marburg, Germany
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
